Nanosizing: a formulation approach for poorly-water-soluble compounds

被引:966
作者
Merisko-Liversidge, E [1 ]
Liversidge, GG [1 ]
Cooper, ER [1 ]
机构
[1] Elan Drug Delivery, King Of Prussia, PA 19406 USA
关键词
poorly-water-soluble compounds; nanoparticles and drug delivery;
D O I
10.1016/S0928-0987(02)00251-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poorly-water-soluble compounds are difficult to develop as drug products using conventional formulation techniques and are frequently abandoned early in discovery. The use of media milling technology to formulate poorly-water-soluble drugs as nanocrystalline particles offers the opportunity to address many of the deficiencies associated with this class of molecules. NanoCrystal((R)), Technology is an attrition process wherein large micron size drug crystals are media milled in a water-based stabilizer solution. The process generates physically stable dispersions consisting of nanometer-sized drug crystals. Nanocrystalline particles are a suitable delivery system for all commonly used routes of administration, i.e. oral, injectable (IV, SC, and IM) and topical applications. In addition, aqueous dispersions of nanoparticles can be post-processed into tablets, capsules, fast-melts and lyophilized for sterile product applications. The technology has been successfully incorporated into all phases of the drug development cycle from identification of new chemical entities to refurbishing marketed products for improving their performance and value. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 61 条
[1]   TUMORICIDAL ACTIVITY OF KUPFFER CELLS AUGMENTED BY ANTICANCER DRUGS [J].
ADACHI, Y ;
ARII, S ;
FUNAKI, N ;
HIGASHITSUJI, H ;
FUJITA, S ;
FURUTANI, M ;
MISE, M ;
ZHANG, WH ;
TOBE, T .
LIFE SCIENCES, 1992, 51 (03) :177-183
[2]   Excipient-drug interactions in parenteral formulations [J].
Akers, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (11) :2283-2300
[3]   Liposomes - Opportunities in drug delivery [J].
Allen, TM .
DRUGS, 1997, 54 (Suppl 4) :8-14
[4]  
Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO
[5]  
2-J
[6]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[7]  
Bittner B, 2002, CURR OPIN DRUG DI DE, V5, P59
[8]   Melt extrusion: from process to drug delivery technology [J].
Breitenbach, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (02) :107-117
[9]   PHARMACEUTICAL SOLIDS - A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS [J].
BYRN, S ;
PFEIFFER, R ;
GANEY, M ;
HOIBERG, C ;
POOCHIKIAN, G .
PHARMACEUTICAL RESEARCH, 1995, 12 (07) :945-954
[10]  
COOPER E, 2000, NANOTECHNOLOGY S